173 related articles for article (PubMed ID: 17324245)
1. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of ceftazidime in burn patients.
Dailly E; Pannier M; Jolliet P; Bourin M
Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
[TBL] [Abstract][Full Text] [Related]
4. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
Xuan D; Nicolau DP; Nightingale CH
Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin pharmacokinetics in patients with severe burn injuries.
Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.
Georges B; Conil JM; Seguin T; Ruiz S; Minville V; Cougot P; Decun JF; Gonzalez H; Houin G; Fourcade O; Saivin S
Antimicrob Agents Chemother; 2009 Oct; 53(10):4483-9. PubMed ID: 19635962
[TBL] [Abstract][Full Text] [Related]
12. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition.
Seaton C; Ignas J; Muchohi S; Kokwaro G; Maitland K; Thomson AH
J Antimicrob Chemother; 2007 Apr; 59(4):681-9. PubMed ID: 17347177
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
Yukawa E; Mori S; Ueda K; Nakada Y
J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Castro N; Márquez-Caraveo C; Brundage RC; González-Esquivel D; Suárez AM; Góngora F; Jara A; Urizar J; Lanao JM; Jung H
Int J Clin Pharmacol Ther; 2009 Nov; 47(11):679-85. PubMed ID: 19840532
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
Lima-Rogel V; Medina-Rojas EL; Del Carmen Milán-Segovia R; Noyola DE; Nieto-Aguirre K; López-Delarosa A; Romano-Moreno S
J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin population pharmacokinetic analysis in hospitalized patients.
Soy D; López E; Ribas J
Ther Drug Monit; 2006 Dec; 28(6):737-43. PubMed ID: 17164688
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ertapenem in burns patients.
Dailly E; Arnould JF; Fraissinet F; Naux E; Letard de la Bouralière MA; Bouquié R; Deslandes G; Jolliet P; Le Floch R
Int J Antimicrob Agents; 2013 Jul; 42(1):48-52. PubMed ID: 23578794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
